About

Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins. For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins. About Arvinas Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins. For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.